Navigation Links
A Phase III Alzheimer's Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits
Date:7/14/2009

served a robust decrease in the number of tau tangles in the brains of the mice immunized with the phosphorylated tau-peptides (~40%; p<0.001), and detected anti-phosphorylated-tau antibodies in mouse serum. They found no evidence or symptoms of brain inflammation in the immunized mice.

According to Rosenmann, the decrease in tau tangles observed by her team is in accord with previous findings by Asuni's group, though Asuni immunized with a different phosphorylated tau peptide and immunization protocol.

"We believe that these results point to the therapeutic potential of phosphorylated-tau-immunotherapy in Alzheimer's," Rosenmann said. "We devoted significant effort to address not only the anti-tangle effect but also safety of a phosphorylated-tau vaccine. This was done in order to identify early in the preclinical stage any potential hazard of this potential Alzheimer's therapy."

Neurologists Views MCI as a Useful Clinical Diagnosis - Practice Guidelines Are Needed

Mild cognitive impairment (MCI) is a category of cognitive status that is used in research to define the state between normal aging and Alzheimer's, and it is now entering clinical practice. Little is known about how it is being used by clinicians or how they view the benefits and limitations of MCI as a clinical category.

In MCI, a person has problems with memory, language, or another mental function severe enough to be noticeable to other people and to show up on tests, but not serious enough to interfere with their daily life. Because the problems do not interfere with daily activities, the person is not diagnosed with Alzheimer's or another dementia. The best-studied type of MCI involves a memory problem and is called "amnestic MCI."

Research has shown that people with MCI have an increased risk of developing Alzheimer's over the next few years, especially when their mai
'/>"/>

SOURCE Alzheimer's Association
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... fill/finish of nimotuzumab , ... ... of Therapure Biopharma Inc. and David Allan, Chairman and CEO ... agreement under which Therapure Biopharma will provide aseptic fill and ... YM’s majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre ...
(Date:12/17/2009)... (NYSE: CFN ) announced today that it ... TRC Capital Corporation (TRC) to purchase up to four ... percent of the shares of common stock outstanding. TRC,s ... below the share closing price of CareFusion common stock ... prior to the offer. CareFusion also noted that the ...
(Date:12/17/2009)... December 17 Researchers from the School ... University in the UK are today,encouraging families ... the,New Year following concerning research* that shows two-thirds ... as a family (68%), with the,Portuguese being the ... to,walk together. , According ...
(Date:12/17/2009)... levels trended in 2009 and over the past three years and ... ... (Vocus) December 17, 2009 -- Morehead, the human capital research firm, ... Year in Review.” The free hour-long webinar will be broadcast ... , ,Join Rod Wilkes, M.S., Morehead’s SVP, Consulting Services and Trevor ...
(Date:12/17/2009)... Cost/Risk Analysis reports, activity measures and outcomes reporting to monitor ... reduced claim costs and positive return on investment over the ... ... Jacksonville, FL (PRWEB) December 17, 2009 -- HealthScreen ... clinical/claims based cost risk analysis along with personalized nurse care, ...
Breaking Medicine News(10 mins):Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 2Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 3Health News:Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership 4Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:Morehead Presents Webinar on "The State of Employee Engagement: A Year in Review" 2Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2
... Rapid improvement in verbal abilities, word finding, and aphasia in Alzheimer,s ... immune treatment is reported. These findings may be related to immune ... research. , ... Los Angeles, CA (PRWEB) August 5, ...
... Award-Winning Actress, Singer and Author to Serve as Emcee at ... September 7 Beverly Hilton ... will join together at the Los Angeles Jewish Home,s 8th Annual,Celebration ... Hotel. The event will honor Jacqui Fogel, Dorothy Goren, and Reggie,Scheer ...
... Children who are given antibiotics in their first three months often ... probably more due to the presence of chest infections than to ... research carried out by researchers in New Zealand, and published in ... This work built on the fact that the prevalence both of ...
... InNexus,Biotechnology Inc., (TSX VENTURE: IXS.V; OTC Bulletin Board: ... the,next generation of monoclonal antibodies based on its ... of a new product,designated DXLr120 (CD20). This is ... and was developed using new recombinant methods to ...
... a Million Patients Using New Drug Safety Monitoring Service; ... 30,000 More Register ... half a,million Americans now have the safety of their medications automatically,monitored ... new patients registering weekly., Founded by drug safety researchers in ...
... Care,Innovations, LLC, a subsidiary of Wound Management Technologies, ... has entered into a,confidentiality agreement with a company ... products, CellerateRx(R), in Taiwan. "We have,had a tremendous ... states Cathy Bradshaw, President of Wound Care,Innovations. "We ...
Other Medicine News:Health News:New Drug May Help Combat Alzheimer's 2Health News:New Drug May Help Combat Alzheimer's 3Health News:Three Noted 'Women of Valor' to be Honored at Los Angeles Jewish Home Gala Dinner 2Health News:Three Noted 'Women of Valor' to be Honored at Los Angeles Jewish Home Gala Dinner 3Health News:Wheezing after early-life antibiotics 2Health News:InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds 2Health News:InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds 3Health News:iGuard.org Reaches 500,000-Member Milestone 12 Months Early 2Health News:Wound Management Technologies, Inc. Announces Products to Be Registered in Taiwan 2
(Date:12/16/2009)... 16 Today, a group of national medical ... H.R. 3590, the Patient Protection and Affordable Care Act, ... its way towards a final vote in the coming ... Senators to vote against a health care bill that ... first hand that our health care system needs reform ...
(Date:12/16/2009)... to Millennium Research Group (MRG), the global authority ... minimally invasive spinal fusion market will expand at ... through 2014, reimbursement concerns in certain segments will ... had been forecast at almost 20%. ,, MRG,s ... 2010 report finds that the ...
(Date:12/16/2009)... -- HDT Engineered Technologies (HDT), a leader in ... principal subcontractor for the mechanical development of the ... anthropromorphic arm technology that will give patients improved, ... including a sense of touch. ,, As ... (DARPA) Revolutionizing Prosthetics 2009 (RP2009) project, the MPL ...
Breaking Medicine Technology:Physician Groups Oppose Current Senate Health Care Reform Bill 2Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 2Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 3HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2Smog Tougher on the Obese 59542 1Smog Tougher on the Obese 59542 2Smog Tougher on the Obese 59542 3ResearchToolkit org provides one stop Web resource for health researchers 59539 1ResearchToolkit org provides one stop Web resource for health researchers 59539 2ResearchToolkit org provides one stop Web resource for health researchers 59539 3Smoking bans reduce the risk of heart attacks associated with secondhand smoke 59536 1Smoking bans reduce the risk of heart attacks associated with secondhand smoke 59536 2
... ROCHESTER, N.Y., May 02, 2007 /PRNewswire/ -- A new ... winter may have been,less effective than the vaccines used ... before last winter were only 24 percent,less likely to ... The,differences were larger in two previous Harris Polls on ...
... the range of migraine symptoms, BOSTON, May 02, ... symptoms such as nausea or,sensitivity to light and ... pain or sinus pain that are not traditionally,associated ... patients using the investigational migraine,treatment Trexima early in ...
Other Medicine Technology:Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 2Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 3Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 4Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 5Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 6Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 2Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 3Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 4Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 5
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
... an affordable path to Sonesta flexibility. ... and back adjustments. Packaged with basic ... line of Sonesta add-ons, allowing you ... your needs; complete Sonesta flexibility at ...
... The Sonesta 6202 is the ... with our most popular accessories, ... for a myriad of exam ... (yet quiet) motors allow fast ...
... The BiliChek measures total serum bilirubin ... no risk of infection compared to the ... Using light, BiliChek tests bilirubin levels without ... Only the replaceable plastic tip touches the ...
Medicine Products: